The Chemopreventive Agent Sulindac Attenuates Expression of the Antiapoptotic Protein Survivin in Colorectal Carcinoma Cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 2, 2004, Pages 434-437

  Zhang, Tao ^a   Fields, Jeremy Z ^b   Ehrlich, Saundra M ^a   Boman, Bruce M ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CATX Inc   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; SULINDAC; SURVIVIN; T CELL FACTOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER PREVENTION; CANCER REGRESSION; CARCINOMA CELL; CELL CULTURE; CELL STRAIN HT29; COLON ADENOMA; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; GENETICS; HUMAN; HUMAN CELL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; GENE EXPRESSION; HT29 CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SULINDAC; TUMOR CELLS, CULTURED;

EID: 1642539021     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.059378     Document Type: Article

References (37)

1. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, and Altieri DC (1998) Developmentally regulated expression of the novel anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49.
2. Ambrosini G, Adida C, and Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 3:917-921.
3. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, and Kinzler KW (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17:1757-1760.
4. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, and Stukenberg PT (2002) Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 13:3064-3077.
5. Boman BM, Zhang T, and Fields JZ (2004) Evidence that APC regulates survinin expression: a possible mechanism contributing to the stem cell origin of colon cancer (Letter to the Editor). Cancer Res, in press.
6. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D, and O'Brien PE (2001a) Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48:660-666.
7. Brown WA, Skinner SA, Vogiagis D, and O'Brien PE (2001b) Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal anti-inflammatory drugs in colorectal cancer. Dig Dis Sci 46:2314-2321.
8. Chen J, Jin S, Tahir SK, Zhang H, Liu X, Sarthy AV, McGonigal TP, Liu Z, Rosenberg SH, and Ng SC (2003) Survivin enhances aurora B kinase activity and localizes aurora B in human cells. J Biol Chem 278:486-490.
9. Fournier DB and Gordon GB (2000) COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem 34 (Suppl):97-102.
10. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 328: 1313-1316.
11. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054-1059.
12. He T-C, Chan TA, Vogelstein B, and Kinzler WK (2000) PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345.
13. Hoffman W, Biade S, Zilfou JT, Chen J, and Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257.
14. Keller JJ, Offerhaus GJ, Frillenburg P, Caspers E, Musler A, Ristimaki A, and Giardiello FM (2001) Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res 7:4000-4007.
15. Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kawasaki H, and Hasegawa J (2000) Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 47:812-819.
16. Li H, Liu L, David ML, Whitehead CM, Chen M, Getter JR, Sperl GJ, Pamukcu R, and Thompson WJ (2002) Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64:1325-1335.
17. Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, and Bertagnolli MM (1997) Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 57:5045-5050.
18. Marx J (2001) Anti-inflammatories inhibit cancer growth-but how? Science (Wash DC) 291:581-582.
19. Masunaga R, Kohno H, Dhar DK, Kotoh T, Tabara H, Tachibana M, Kubota H, and Nagasue N (2001) Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after sulindac therapy. Dis Colon Rectum 44:1008-1015.
20. Masunaga R, Kohno H, Kumar DD, Kotoh T, Tachibana M, Kubota H, and Nagasue N (2000) Sulindac inhibits growth of rat colon carcinoma by inducing apoptosis. Eur Surg Res 32:305-309.
21. Mattila J, Mantyla R, Vuoreta A, Lamminsivu U, and Mannisto P (1984) Pharmacokinetics of graded oral doses of sulindac in man. Arzneim-Forsch 34:226-229.
22. McEntee MF, Chiu CH, and Whelan J (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20:635-640.
23. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Want L, Kirschmeier P, Bishop WR, et al. (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622.
24. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, and Hirohashi S (2001) Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 61:2751-2758.
25. Patrignani P (2000) Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. Toxicol Lett 112-113:493-498.
26. Ravis WR, Diskin CJ, Campagna KD, Clark CR, and McMillian CL (1993) Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33:527-534.
27. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, and Ahnen DJ (2003) Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2:885-892.
28. Richter M, Weiss M, Weinberger I, Furstenberger G, and Marian B (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 22:17-25.
29. Schnitzler M, Dwight T, and Robinson BG (1996) Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Gut 38:707-713.
30. Shiff SJ, Qiao L, Tsai LL, and Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Investig 96:491-503.
31. Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, and Skovan BA (2000) Sulindac sulfone inhibits k-ras dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 60:6607-6610.
32. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sprel G, Ahnen D, and Pamukcu R (2000) Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated beta-catenin. Cancer Res 60:3338-3342.
33. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, and Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nature Med 6:1024-1028.
34. Waddell WR and Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24:83-88.
35. Zhang L, Yu J, Park BH, Kinzler KW, and Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science (Wash DC) 290:989-992.
36. Zhang T, Otevrel T, Gao ZQ, Gao ZP, Ehrlich SM, Fields JZ, and Boman BM (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61:8664-8667.
37. Zhou M, Gu L, Li F, Zhu Y, Woods WG, and Findley HW (2002) DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 303:124-131.